Exagen Q3 2025 Earnings Report

Exagen EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.13
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Exagen Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $16.90 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Exagen Announcement Details

• Quarter: Q3 2025
• Date: 11/4/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, November 4, 2025
• Conference Call Time: 8:30AM ET

Exagen (NASDAQ:XGN) Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel. These tests combine proprietary immunoassay technology with algorithm-driven analysis to deliver more precise and actionable diagnostic insights. All assays are performed in Exagen’s CLIA-certified, CAP-accredited laboratory to ensure consistent quality and reliability.

Exagen works closely with rheumatologists, immunologists and other healthcare providers across the United States, and is pursuing strategic partnerships to extend its reach into European markets. By filling critical gaps in standard autoimmune testing, the company aims to support earlier diagnosis, guide treatment decisions and improve long-term patient outcomes.

The company is led by President and Chief Executive Officer Stephen Heyser, whose background spans diagnostics, biotech and laboratory services. Under his leadership, Exagen continues to invest in research and development to enhance its existing testing platform and explore new assay applications within the autoimmune space.